PPARγ is functionally expressed in clear cell renal cell carcinoma

International Journal of Oncology

Volumn 38, Issue 3, 2011, Pages 851-857

  Collet, Nicolas ^a   Théoleyre, Sandrine ^a   Rageul, Julie ^a   Mottier, Stéphanie ^a   Jouan, Florence ^a   Rioux Leclercq, Nathalie ^a   Fergelot, Patricia ^a   Patard, Jean Jacques ^a   Masson, Damien ^a   Denis, Marc G ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Clear cell renal cell carcinoma; Multiplex ligation dependent probe amplification; Peroxisome proliferator activated receptor

Indexed keywords

ANGIOPOIETIN LIKE 4 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CELL CULTURE; CELL LINE; CHROMOSOME 3P; CLEAR CELL CARCINOMA; CLEAR CELL KIDNEY CARCINOMA; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 79952034503     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.891     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Patard J-J, Pouessel D, Bensalah K and Culine S: Targeted therapy in renal cell carcinoma. World J Urol 26: 135-140, 2008.
3. Motzer RJ and Bukowski RM: Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601-5608, 2006. (Pubitemid 46631341)
4. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
5. Berger J and Moller DE: The mechanism of action of PPARs. Annu Rev Med 53: 409-435, 2002.
6. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688, 1999. (Pubitemid 30650602)
7. Rosen ED and Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276: 37731-37734, 2001.
8. Fajas L, Debril MB and Auwerx J: Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 27: 1-9, 2001. (Pubitemid 32771453)
9. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052, 1998. (Pubitemid 28417337)
10. Wang X, Southard RC and Kilgore MW: The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res 64: 5592-5596, 2004. (Pubitemid 39095554)
11. Han S, Zheng Y and Roman J: Rosiglitazone, an agonist of PPARgamma, inhibits non-small cell carcinoma cell proliferation in part through activation of tumor sclerosis complex-2. PPAR Res 2007: 29632, 2007.
12. Martelli ML, Iuliano R, Le Pera I, et al: Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 87: 4728-4735, 2002. (Pubitemid 35247068)
13. Fu YG, Sung JJ, Wu KC, et al: Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J2 through the downregulation of angiopoietin-1. Cancer Lett 243: 246-254, 2006. (Pubitemid 44485851)
14. Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
15. Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58: 1-14, 2006.
16. Yoshizumi T, Ohta T, Ninomiya I, et al: Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
17. Gupta RA, Brockman JA, Sarraf P, Willson TM and DuBois RN: Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem 276: 29681-29687, 2001.
18. Yuan J, Takahashi A, Masumori N, et al: Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma. Urology 65: 594-599, 2005. (Pubitemid 40386032)
19. Yang FG, Zhang ZW, Xin DQ, et al: Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26: 753-761, 2005.
20. York M, Abdelrahim M, Chintharlapalli S, Lucero SD and Safe S: 1,1-Bis(3′-Indolyl)-1-(p-Substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clin Cancer Res 13: 6743-6752, 2007. (Pubitemid 350206812)
21. Greene ME, Blumberg B, McBride OW, et al: Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4: 281-299, 1995.
22. Barry RE and Krek W: The von Hippel-Lindau tumor suppressor: a multi-faceted inhibitor of tumorigenesis. Trends Mol Med 10: 466-472, 2004. (Pubitemid 39209214)
23. Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54: 2852-2855, 1994.
24. Patard JJ, Rioux-Leclercq N, Masson D, et al: Absence of VHL gene alteration and high VEGF expression are associated with tumor aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer 101: 1417-1424, 2009.
25. Banks RE, Tirukonda P, Taylor C, et al: Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66: 2000-2011, 2006.
26. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982. (Pubitemid 13234762)
27. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al: Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 109: 868-874, 2007. (Pubitemid 46333528)
28. Guinan P, Sobin LH, Algaba F, et al: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80: 992-993, 1997.
29. Ficarra V, Guille F, Schips L, et al: Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 104: 2116-2123, 2005. (Pubitemid 41579957)
30. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F and Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30: e57, 2002.
31. Fajas L, Auboeuf D, Raspe E, et al: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272: 18779-18789, 1997. (Pubitemid 27318225)
32. Blanchot-jossic F, Jarry A, Masson D, et al: Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J Pathol 207: 156-163, 2005. (Pubitemid 41404146)
33. Rageul J, Mottier S, Jarry A, et al: KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer 125: 2802-2809, 2009.
34. Sarraf P, Mueller E, Smith WM, et al: Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3: 799-804, 1999. (Pubitemid 29323058)
35. Ikezoe T, Miller CW, Kawano S, et al: Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res 61: 5307-5310, 2001. (Pubitemid 32681569)
36. Matsuyama M and Yoshimura R: A novel approach to anticancer therapies: peroxisome proliferator activator-receptor-gamma as a new target therapy in the treatment of human urological cancer. Endocr Metab Immune Disord Drug Targets 9: 76-83, 2009.
37. Yuan J, Takahashi A, Masumori N, Itoh N and Tsukamoto T: Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma. Int J Urol 13: 265-270, 2006.
38. Hauner H: The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18 (Suppl. 2): S10-S15, 2002.
39. Margeli A, Kouraklis G and Theocharis S: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 6: 165-169, 2003. (Pubitemid 38506661)
40. Han S and Roman J: Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 18: 237-244, 2007.
41. Bouancheau D, Buecher B, Jarry A, et al: The PPAR(gamma) K422Q mutation does not contribute to troglitazone inefficiency in colon cancer treatment. Cancer Lett 224: 111-116, 2005. (Pubitemid 40720372)
42. Posch MG, Zang C, Mueller W, Lass U, von Deimling A and Elstner E: Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monit 10: BR250-254, 2004.
43. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE and Tartof KD: Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 55: 6189-6195, 1995.
44. Sukosd F, Kuroda N, Beothe T, Kaur AP and Kovacs G: Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 63: 455-457, 2003. (Pubitemid 36152507)
45. Le Jan S, Amy C, Cazes A, et al: Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. Am J Pathol 162: 1521-1528, 2003. (Pubitemid 36512834)
46. Kulke MH, Demetri GD, Sharpless NE, et al: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 8: 395-399, 2002.
47. Zhang YQ, Tang XQ, Sun L, et al: Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J Gastroenterol 13: 1534-1540, 2007. (Pubitemid 46672661)
48. Girnun GD, Chen L, Silvaggi J, et al: Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14: 6478-6486, 2008.
49. Girnun GD, Naseri E, Vafai SB, et al: Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 11: 395-406, 2007. (Pubitemid 46670076)
50. Yu HN, Noh EM, Lee YR, et al: Troglitazone enhances tamoxifen-induced growth inhibitory activity of MCF-7 cells. Biochem Biophys Res Commun 377: 242-247, 2008.